Skip to content
View in the app

A better way to browse. Learn more.

Thailand News and Discussion Forum | ASEANNOW

A full-screen app on your home screen with push notifications, badges and more.

To install this app on iOS and iPadOS
  1. Tap the Share icon in Safari
  2. Scroll the menu and tap Add to Home Screen.
  3. Tap Add in the top-right corner.
To install this app on Android
  1. Tap the 3-dot menu (⋮) in the top-right corner of the browser.
  2. Tap Add to Home screen or Install app.
  3. Confirm by tapping Install.

Moderna's new Omicron-targeted booster shot shows promise

Featured Replies

Screenshot_2.jpg.542527f4f0ebe769bcafbd09970666fc.jpg

 

Company says they hope the new vaccine can provide six to nine months of protection

 

Moderna’s MRNA experimental next-generation COVID-19 vaccine provides more protection against omicron than the original shot, and the company is aiming to make it available to Americans this summer.

 

What’s different about this shot — called a “bivalent” vaccine — than the currently available boosters is that one half of the formation targets omicron, whose subvariants like BA.2 and BA.2.12.1 are currently the most dominant strains of the virus circulating in the U.S. 

 

The other half is still based on the ancestral strain of SARS-CoV-2, which was first detected in China in 2019. All approved and authorized COVID-19 vaccines are based are on this strain.

 

“We’re pretty confident that this vaccine is going to provide a benefit even against the family of omicron variants and subvariants,” Moderna President Stephen Hoge said during a call with investors on Wednesday.

 

(more)

 

https://www.marketwatch.com/story/modernas-next-generation-covid-19-shot-provides-superior-protection-against-omicron-11654703308?mod=investing

 

MarketWatch.jpg.77ba3a18202261c6a41a2f436f469ef6.jpg

 

 

Also:

Moderna Announces Omicron-Containing Bivalent Booster Candidate mRNA-1273.214 Demonstrates Superior Antibody Response Against Omicron

 

CAMBRIDGE, MA / ACCESSWIRE / June 8, 2022 / Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced new clinical data on its Omicron-containing bivalent COVID booster candidate, mRNA-1273.214, containing mRNA-1273 (Spikevax) and a vaccine candidate targeting the Omicron variant of concern. A 50 µg booster dose of mRNA-1273.214 met all pre-specified endpoints including superior neutralizing antibody response (geometric mean ratio) against the Omicron variant one month after administration when compared to the original mRNA-1273 vaccine. The booster dose of mRNA-1273.214 was generally well-tolerated, with side effects comparable to a booster dose of mRNA-1273 at the 50 µg dose level.

 

"We are thrilled to share the preliminary data analysis on mRNA-1273.214, which is the second demonstration of superiority of our bivalent booster platform against variants of concern and represents an innovation in the fight against COVID," said Stéphane Bancel, Chief Executive Officer of Moderna.

 

(more)

 

https://investors.modernatx.com/news/news-details/2022/Moderna-Announces-Omicron-Containing-Bivalent-Booster-Candidate-mRNA-1273.214-Demonstrates-Superior-Antibody-Response-Against-Omicron/default.aspx

 

 

 

Create an account or sign in to comment

Recently Browsing 0

  • No registered users viewing this page.

Account

Navigation

Search

Search

Configure browser push notifications

Chrome (Android)
  1. Tap the lock icon next to the address bar.
  2. Tap Permissions → Notifications.
  3. Adjust your preference.
Chrome (Desktop)
  1. Click the padlock icon in the address bar.
  2. Select Site settings.
  3. Find Notifications and adjust your preference.